Get the latest news, insights, and market updates on TWST (Twist Bioscience Corporation). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Barclays Keeps Its Overweight Rating On Twist Bioscience Corporation (TWST)
Twist Bioscience Corporation (NASDAQ:TWST) is among the 12 Best Genomics Stocks to Invest In. TheFly reported on December 15, 2025, that Barclays kept its Overweight rating and boosted its price objective for Twist Bioscience Corporation (NASDAQ:TWST) from $37 to $39. The move was included in the company’s more comprehensive 2026 outlook report for the life […] Dec 31, 2025 - $TWST
New Product Launch Strengthens Bull Case for Twist Bioscience ( TWST)
We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Twist Biosciences Corporation is one of the most promising stocks on our list. TheFly reported on December 15 that Barclays raised its price target for TWST from $37 to $39 while maintaining an Overweight rating, reflecting confidence in the company’s margin […] Dec 23, 2025 - $TWST
Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., December 18, 2025--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 2:15 pm Pacific Time in San Francisco. Dec 18, 2025 - $TWST
Twist Bioscience (TWST): Valuation Check After New Research-Grade Plasmid DNA Preps Boost Investor Interest
Twist Bioscience (TWST) just rolled out research grade Plasmid DNA Preps tailored for pre clinical pharma and biotech work, a small but telling move that helps explain the recent uptick in the stock. See our latest analysis for Twist Bioscience. The launch of pre clinical Plasmid DNA Preps comes on the heels of Twist consolidating its South San Francisco offices. The market seems to be noticing, with a 30 day share price return of 9.15 percent and a 90 day share price return of 27.37 percent,... Dec 5, 2025 - $TWST
How Twist’s New Preclinical-Grade Plasmid DNA Preps Could Reshape the TWST Nucleic Acid Therapeutics Story
In early December 2025, Twist Bioscience launched research-grade Plasmid DNA Preps with animal origin-free and endotoxin-free options tailored to stringent preclinical study requirements. This move strengthens Twist’s role in nucleic acid therapeutics workflows by offering consistent, specification-matched DNA that can help reduce variability and risk for pharma and biotech customers. We’ll now explore how this expansion into high-quality plasmid DNA preps may influence Twist Bioscience’s... Dec 4, 2025 - $TWST
Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research
SOUTH SAN FRANCISCO, Calif., December 04, 2025--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to support the advancement of pharmaceutical and biotech customers’ pre-clinical studies. Dec 4, 2025 - $TWST
Stephens Initiates Twist Bioscience (TWST) With Overweight Rating, Sets $41 PT
Twist Bioscience Corporation (NASDAQ:TWST) is one of the best gene-editing stocks to buy according to hedge funds. On November 4, Steven Etoch, an analyst at Stephens, began coverage of Twist Bioscience Corporation (NASDAQ:TWST). Etoch assigned an Overweight rating on the stock and a $41 price target. The analyst cited Twist’s “differentiated, technology-driven DNA synthesis platform” […] Nov 18, 2025 - $TWST
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple